Introduction {#sec1_1}
============

Papillary tumor of the pineal region (PTPR) is a rare tumor with no known effective systemic therapy. We report here the first case of demonstrable radiologic response to a systemic therapy, bevacizumab, in multiple recurrent PTPR.

Case Report {#sec1_2}
===========

A 31-year-old right-handed man was referred for treatment of recurrent PTPR in the posterior fossa with symptoms including headache, inability to open his eyes, confusion, and obstructive hydrocephalus. He originally presented at 24 years of age with obstructive hydrocephalus and a 1.5-cm enhancing pineal mass. Following placement of a ventriculoperitoneal shunt and a nondiagnostic biopsy, he underwent craniotomy and resection. The pathology report showed a papillary neoplasm negative for GFAP, synaptophysin, PLAF, and MEC, and positive for CAM 5.2 and cytokeratin 3. The MIB-1 index was 15%. The pathology was reviewed at Johns Hopkins University and has subsequently been reviewed by us; the diagnosis has been confirmed to be PTPR (fig. [1](#F1){ref-type="fig"}). Because of residual tumor, he received 5,940 cGy of radiotherapy in 33 fractions.

Seven months later, he developed a new 1-cm enhancing mass in the left lateral ventricle that increased in size over 3 months. New lesions also developed in the posterior fossa, and he was treated with Gamma Knife to 5 locations. Eighteen months later, he had Gamma Knife to 4 additional posterior fossa lesions, resulting in shrinkage of the lesions on MRI and decreased steroid requirement. Over the next 2 years, he had waxing and waning enhancement over the right inferior temporal lobe that was treated as radiation necrosis with pentoxifylline and vitamins, with subsequent resolution of the enhancement.

By the age of 28, he had increased edema and mass effect in the left cerebellum and underwent a posterior fossa craniotomy. The specimen was about 70% necrosis and gliosis and 30% viable PTPR. Because of residual enhancement, dose-dense temozolomide (75 mg/m^2^ for 21 days of a 28-day cycle) was given for 11 cycles. He then developed increased enhancement and worsening balance while on the temozolomide and was treated with 2 cycles of PCV and 2 cycles of carboplatin and etoposide.

His MRI then showed stable 1-cm lesions in the occipital lobe but an enlarging 4.6 × 3.2 × 2.8-cm mass in the midline posterior cerebellum and a 1.7 × 1 × 2.8-cm mass abutting the fourth ventricle, both with surrounding edema and mass effect, and he was referred to the University of Utah (fig. [2](#F2){ref-type="fig"}). An extraventricular drain was placed, followed by a ventriculoperitoneal shunt. Reirradiation was recommended, but the patient declined due to prior toxicity.

Twelve days later, at the age of 31, he began bevacizumab 10 mg/kg every 2 weeks. The enhancing midline cerebellar mass decreased in size to 2 × 1.4 × 2.8 cm (80% decrease in the cross-sectional area) and the periventricular mass decreased to 1.7 × 0.8 × 0.9 cm in 1 month (20% decrease in the cross-sectional area), and both remained stable for 13 months. The FLAIR signal remained decreased as well (fig. [3](#F3){ref-type="fig"}). His dexamethasone dose remained at 2 mg daily for 6 months and then was tapered off.

After 13 months, both masses increased in size to 3.1 × 1.9 cm (120%) and 2.2 × 1.1 cm (84%) in cross-sectional area, respectively (fig. [4](#F4){ref-type="fig"}). Oral etoposide 50 mg/m^2^ for 21 out of 28 days was added, and his mass remained stable on MRI at 2, 5 (fig. [5](#F5){ref-type="fig"}: white arrow indicates tumor; black arrow indicates shunt), and 7 months. After 7 months of bevacizumab and etoposide, he had increased dysarthria and ataxia, and MRI demonstrated growth of the masses by 220% in cross-sectional area to 5.6 × 3.5 cm and by 100% to 3.1 × 1.7 cm. He again declined radiation and has continued on bevacizumab and etoposide. His dexamethasone dose has varied between 1 and 2 mg per day.

Discussion {#sec1_3}
==========

PTPR is a rare tumor originally described in 2003 \[[@B1]\] and accepted into the WHO classification of central nervous system tumors in 2007 \[[@B2]\]. Fewer than 100 cases have been reported, with most focusing on the histologic or radiologic appearance. The cell of origin of PTPR is unknown. Based on the location and immunohistochemical staining pattern, it has been proposed to be of ependymal cell origin from the circumventricular organs \[[@B3], [@B4]\]. Therefore, treatments effective for gliomas may be effective for PTPR. However, data on successful systemic therapy for PTPR are lacking, and optimal therapy for recurrent PTPR is not well characterized. In our case, prolonged stabilization was seen with both etoposide and bevacizumab. Bevacizumab also greatly improved his quality of life.

PTPR has been described as very vascular \[[@B5]\], but microvascular proliferation has not been noted. However, most pathologic descriptions of PTPR are from primary or early resections, rather than from recurrences. In 1 case, a resected recurrent PTPR had an increased proliferation rate, increased anaplasia, and necrosis without microvascular proliferation \[[@B6]\].

In published series, the primary treatment for PTPR has been surgery and/or radiation/radiosurgery \[[@B7], [@B8], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15], [@B16], [@B17], [@B18], [@B19]\]. Neither radiation nor chemotherapy has been shown to improve survival \[[@B20]\]. Other treatments for PTPR have included adjuvant and neoadjuvant temozolomide after complete resection, adjuvant temozolomide/etoposide after complete resection, adjuvant carboplatin/etoposide following resection, and ACNU given after radiation but before surgery \[[@B6], [@B7], [@B21], [@B22]\]. When the treatment was either adjuvant after surgery and/or radiation or concomitant with radiation, the independent effect of the systemic chemotherapy could not be assessed. In another single patient report, a woman with recurrent PTPR had a partial response to temozolomide that was started due to lack of change in the tumor 2 months after radiation \[[@B21]\]. Due to the timing, the independent effects of radiation and temozolomide in that case cannot be known for certain, but it suggests a sensitivity to temozolomide. In another case, the treatment effect was not noted after neoadjuvant treatment with temozolomide \[[@B6]\].

Bevacizumab is an antiangiogenic antibody against vascular endothelial growth factor. Responses have been reported in ependymoma \[[@B23]\], which is of interest relative to the case reported here due to the potential, commonly hypothesized origin of ependymoma and PTPR from cells in the ependymal region. Here, we describe a successful long-term response to bevacizumab in a multiple recurrent and chemotherapy-resistant PTPR. Thus, bevacizumab may be an active agent in this rare tumor and should be considered for cases of recurrent PTPR that are not operable or amenable/responsive to radiation or standard cytotoxic treatments.

![HE-stained sections of the tumor demonstrate an epithelial tumor with papillary features (left; HE ×400). The tumor is strongly positive for keratin immunostaining (right; Cam5.2 ×600).](cro-0006-0434-g01){#F1}

![MRI of the tumor 2 months before (**a**, **b**) and then again immediately before (**c**, **d**) bevacizumab treatment. **a** Magnetic resonance (MR) axial T2 image of the posterior fossa shows a large heterogeneous mass (white arrow) in the posterior cerebellum with surrounding hyperintense signal likely related to vasogenic edema and treatment effects. **b** Post-contrast T1-weighted image with fat saturation shows heterogeneous enhancement of the mass (white arrow) related to the patient\'s known metastatic disease from his PTPR. **c** MR axial FLAIR image of the posterior fossa shows an increase in the size of the heterogeneous mass (white arrow) in the posterior cerebellum with surrounding hyperintense signal likely related to vasogenic edema and treatment effects. **d** Post-contrast T1-weighted image with fat saturation shows an increase in heterogeneous enhancement of the mass (white arrow) related to the patient\'s known metastatic disease from his PTPR. The mass measured 4.6 cm. A linear focus of enhancement along the left fourth ventricle is related to the patient\'s metastatic disease.](cro-0006-0434-g02){#F2}

![MRI of the tumor after bevacizumab treatment. **a** Magnetic resonance axial FLAIR image of the posterior fossa shows a decrease in the size of the heterogeneous mass (white arrow) in the posterior cerebellum with a decrease in the associated edema after bevacizumab. The extraventricular drain is partially visualized (black arrow). **b** Post-contrast T1-weighted image with fat saturation shows a decrease in the heterogeneously enhancing mass (white arrow) after bevacizumab. The mass measured 2 cm and was stable for 13 months. The extraventricular drain is partially visualized (black arrow).](cro-0006-0434-g03){#F3}

![MRI of the tumor after 13 months of bevacizumab treatment. **a** Magnetic resonance axial FLAIR image of the posterior fossa shows an increase in the size of the heterogeneous mass (white arrow) in the posterior cerebellum with an increase in the associated edema. The extraventricular drain is partially visualized (black arrow). **b** Post-contrast T1-weighted image with fat saturation shows an increase in the heterogeneously enhancing mass (white arrow) after bevacizumab. The extraventricular drain is partially visualized (black arrow).](cro-0006-0434-g04){#F4}

![MRI of the tumor after 5 months of bevacizumab and etoposide treatment. **a** Magnetic resonance axial FLAIR image of the posterior fossa shows stability in the size of the heterogeneous mass (white arrow) in the posterior cerebellum. The extraventricular drain is partially visualized (black arrow). **b** Post-contrast T1-weighted image with fat saturation shows stability in the heterogeneously enhancing mass (white arrow). The extraventricular drain is partially visualized (black arrow).](cro-0006-0434-g05){#F5}
